Treatment information
Oncology
Professional profile
Dr Daniel Krell undertook his oncology training at University College
Hospital and the Royal Free Hospital in London. In addition, to his
primary medical degree, he also gained a bachelor’s degree in
immunology and microbiology, as well as a DPhil in clinical medicine at
the University of Oxford.
His clinical work focuses on the management of patients with
gastro-oesophageal, colorectal, pancreatic, liver and bile duct cancers and
neuroendocrine tumours, using chemotherapy, targeted therapy and
immunotherapy.
He also manages patients with cancer of unknown primary and is the clinical
lead at his institution for this. He also acts as the MDT lead for
gastro-oesophageal and hepatobiliary cancer at his institution.
Dr Krell’s DPhil research was undertaken at the University of Oxford's
Wellcome Trust Centre for Human Genetics. Dr Krell’s research involved
the design of models to investigate the role that genetic mutations in genes
controlling cellular metabolism play in the development of cancer, with a view
to identifying new therapeutic targets in this area. He continues to be
involved in clinical research and clinical trials aimed at identifying new
cancer therapies, with a focus on gastrointestinal, hepatobiliary and
neuroendocrine tumours.
Dr Krell has published several peer-reviewed papers in journals such as Cancer
Cell, the British Journal of Cancer and Lancet Oncology, and has submitted and
presented abstracts and posters at national and international conferences.
He is a member of the chemotherapy operations group as well as the London
cancer expert reference group for acute oncology and cancer of unknown
primary.
Current NHS posts
Royal Free Hospital
